Gland Pharma shares fall 5% to November 2023 lows after downgrades, target cuts

Share it

Gland Pharma reported another disappointing quarter with weak revenue growth in its base business. Additionally, Gland Pharma faced further drag from its acquired Cenexi business.

Leave a Comment

Your email address will not be published. Required fields are marked *